Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epacadostat + nivolumab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination regimen including **epacadostat**, an oral, selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor; **nivolumab**, a PD-1 immune checkpoint inhibitor; and **chemotherapy**. This regimen is being investigated primarily for advanced solid tumors, including squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), melanoma, colorectal cancer, ovarian cancer, glioblastoma, and diffuse large B-cell lymphoma (DLBCL). Epacadostat works by inhibiting IDO1, an enzyme that suppresses antitumor immunity in the tumor microenvironment, while nivolumab blocks the PD-1 receptor on T cells, releasing PD-1 pathway–mediated inhibition of anti-tumor immune responses. Chemotherapy provides a standard cytotoxic effect and may enhance immunogenicity of cancer cells[1][2][5][7].
- Brand names
- Opdivo (for nivolumab)
- Other names
- epacadostat + Opdivo + chemotherapy
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on epacadostat + nivolumab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epacadostat + nivolumab + chemotherapy.